FI753613A7 - - Google Patents

Info

Publication number
FI753613A7
FI753613A7 FI753613A FI753613A FI753613A7 FI 753613 A7 FI753613 A7 FI 753613A7 FI 753613 A FI753613 A FI 753613A FI 753613 A FI753613 A FI 753613A FI 753613 A7 FI753613 A7 FI 753613A7
Authority
FI
Finland
Application number
FI753613A
Other languages
Finnish (fi)
Other versions
FI62282B (fi
FI62282C (fi
Inventor
Gerhard Satzinger
Manfred Herrmann
Johannes Hartenstein
Wolfgang Heldt
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI753613(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of FI753613A7 publication Critical patent/FI753613A7/fi
Publication of FI62282B publication Critical patent/FI62282B/fi
Application granted granted Critical
Publication of FI62282C publication Critical patent/FI62282C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI753613A 1974-12-21 1975-12-19 Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror FI62282C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2460891 1974-12-21

Publications (3)

Publication Number Publication Date
FI753613A7 true FI753613A7 (forum.php) 1976-06-22
FI62282B FI62282B (fi) 1982-08-31
FI62282C FI62282C (fi) 1982-12-10

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
FI753613A FI62282C (fi) 1974-12-21 1975-12-19 Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror

Country Status (16)

Country Link
US (1) US4024175A (forum.php)
JP (1) JPS5324064B2 (forum.php)
AT (1) AT340892B (forum.php)
BE (1) BE836835A (forum.php)
CA (1) CA1052811A (forum.php)
CH (3) CH612665A5 (forum.php)
DE (1) DE2460891C2 (forum.php)
DK (1) DK147706C (forum.php)
ES (1) ES443723A1 (forum.php)
FI (1) FI62282C (forum.php)
FR (1) FR2294697A1 (forum.php)
GB (1) GB1465229A (forum.php)
IE (1) IE42382B1 (forum.php)
LU (1) LU74058A1 (forum.php)
NL (1) NL181006C (forum.php)
SE (1) SE423385B (forum.php)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (forum.php) * 1980-10-28 1982-05-11
JPS6152583U (forum.php) * 1984-09-11 1986-04-09
JPS61139881U (forum.php) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
PH27359A (en) * 1989-08-25 1993-06-21 Warner Lambert Co Process for cyclic amino acid anticonvulsant compounds
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69712877T2 (de) * 1996-02-07 2002-11-14 Warner-Lambert Co., Morris Plains Zyklischaminosäure als pharmazeutische mittel
AU734173B2 (en) * 1996-03-14 2001-06-07 Warner-Lambert Company Novel substituted cyclic amino acids as pharmaceutical agents
EP0888285B1 (en) * 1996-03-14 2001-12-12 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
NZ334898A (en) * 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
BR9812162A (pt) * 1997-09-08 2000-07-18 Warner Lambert Co Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CU23048A3 (es) * 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
HUP0004439A3 (en) 1997-12-16 2001-12-28 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1045839B1 (en) 1997-12-16 2004-03-03 Warner-Lambert Company LLC Novel amines as pharmaceutical agents
IL135315A0 (en) 1997-12-16 2001-05-20 Warner Lambert Co 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1047414A1 (en) * 1998-01-23 2000-11-02 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
CU23051A3 (es) * 1998-05-15 2005-06-24 Warner Lambert Co Composiciones solidas que contienen derivados de acido gamma-aminobutirico y procesos para prepararlas.
US7309719B1 (en) 1998-05-15 2007-12-18 Warner Lambert Company, Llc Stabilized pharmaceutical preparation of gamma-aminobutyric acid derivatives and process for preparing the same
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
US6316638B1 (en) 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
JP2002541215A (ja) * 1999-04-09 2002-12-03 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬組成物およびその使用
US6710190B1 (en) 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
MXPA01011059A (es) * 1999-05-28 2002-06-04 Warner Lambert Co Analogos gaba 3-heteroarilalquilo sustituidos.
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SK287247B6 (sk) * 1999-06-10 2010-04-07 Warner-Lambert Company Llc Kyselina (3S,5R)-3-aminometyl-5-metyloktánová, jej použitie na výrobu liečiva a farmaceutický prostriedok s jej obsahom
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
YU95302A (sh) * 2000-06-16 2006-05-25 Teva Pharmaceutical Industries Ltd. Stabilni gabapentin koji ima ph u kontrolisanom rasponu
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
AU2001268426A1 (en) 2000-06-16 2002-01-02 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
NZ522480A (en) * 2000-06-26 2005-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
WO2002022568A1 (de) * 2000-09-14 2002-03-21 Grünenthal GmbH β-THIO-AMINOSÄUREN
WO2002032376A2 (en) * 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
US6613904B2 (en) * 2000-11-02 2003-09-02 Teva Pharmaceutical Industries, Ltd Process for production of gabapentin intermediate
CN1477975A (zh) * 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与山梨醇脱氢酶抑制剂的组合
EP1337272A2 (en) * 2000-11-30 2003-08-27 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
JP2004524339A (ja) * 2001-03-16 2004-08-12 ソルケム イタリアーナ エス．ピー．エイ． 環状アミノ酸の調製方法
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1533270A (zh) * 2001-06-11 2004-09-29 ʲŵ�������޹�˾ 具有降低毒性的gaba类似物前药的口服给药剂型
WO2002100344A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
EP1423168B1 (en) * 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
JP2005521664A (ja) * 2002-01-31 2005-07-21 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 耳鳴を治療するためのアルファ２デルタ・リガンド
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
CA2478471A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
IL165593A0 (en) * 2002-06-27 2006-01-15 Warner Lambert Co Use of an alpha2delta ligand such as gabapentin orpregabalin for treating attention deficit hyperac tivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
WO2004046084A1 (en) * 2002-11-18 2004-06-03 Nicholas Piramal India Limited Improved process for preparation of gabapentin
PT1599446E (pt) * 2002-11-20 2009-11-06 Hikal Ltd Um processo melhorado para a preparação de gabalactama
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
PL377662A1 (pl) * 2002-12-13 2006-02-06 Warner-Lambert Company Llc Pregabalina i jej pochodne w leczeniu fibromialgii i innych zaburzeń pokrewnych
EP1572188A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin derivatives for the treatment of fibromyalgia and other disorders
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
JP2006511605A (ja) * 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛及び他の関連障害のためのガバペンチン類縁体
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
WO2004065361A2 (en) * 2003-01-22 2004-08-05 Warner-Lambert Company Llc Cyclopropyl beta-amino acid derivatives
EP1603890A1 (en) * 2003-03-07 2005-12-14 Warner-Lambert Company LLC TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES
EP1628656B1 (en) * 2003-03-25 2008-10-15 Kiel Laboratories, Inc. Gabapentin tannate in liquid and/or semi-solid dosage forms
WO2004093827A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
US20040254246A1 (en) * 2003-03-31 2004-12-16 Barrett Ronald W. Treating or preventing hot flashes using prodrugs of GABA analogs
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
US7439387B2 (en) * 2003-04-21 2008-10-21 Matrix Laboratories Ltd. Process for the preparation of Gabapentin form-II
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
MXPA05013754A (es) * 2003-06-19 2006-03-08 Pfizer Prod Inc Una preparacion biocatalitica del acido 1-cianociclohexanoacetico.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
CA2572324A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7700652B2 (en) * 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
CA2538412A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
SG146643A1 (en) * 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
RU2412162C2 (ru) * 2003-10-14 2011-02-20 Ксенопорт, Инк. Кристаллическая форма аналога y-аминомасляной кислоты
ITMI20032165A1 (it) * 2003-11-11 2005-05-12 Zambon Spa Processo di preparazione di gabapentina
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
EP1737466A1 (en) * 2004-01-29 2007-01-03 Pfizer Products Inc. COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
CA2570255A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
PL1809271T3 (pl) * 2004-09-10 2010-10-29 Newron Pharm Spa Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych
MX2007005306A (es) * 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1937646A1 (en) 2005-09-23 2008-07-02 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
MY148863A (en) * 2005-09-23 2013-06-14 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
SI1937259T1 (sl) * 2005-09-23 2012-02-29 Janssen Pharmaceutica Nv Heksahidro-cikloheptapirazol kanabionidni modulatorji
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7526911B2 (en) * 2006-02-03 2009-05-05 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
KR20080100284A (ko) * 2006-03-06 2008-11-14 화이자 프로덕츠 인코포레이티드 비-회복성 수면을 위한 알파-2-델타 리간드
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
CN101484413B (zh) * 2006-06-30 2014-05-14 Zach系统股份公司 制备加巴喷丁的方法
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças
ATE511860T1 (de) 2006-12-22 2011-06-15 Recordati Ireland Ltd Kombinationstherapie für erkrankungen der unteren harnwege mit 2 liganden und nsar
BRPI0808962A2 (pt) * 2007-03-15 2014-08-26 Sun Pharma Advanced Res Co Ltd Agente para drogas
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2368872A1 (en) 2010-03-25 2011-09-28 Serichim S.r.l. Process for the preparation of Gabapentin
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
IN2012MN02923A (forum.php) 2010-06-01 2015-06-05 Rubicon Res Private Ltd
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
EP2599487B1 (en) 2010-07-30 2015-04-01 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
JP2013216580A (ja) * 2010-08-06 2013-10-24 Kyorin Pharmaceutical Co Ltd ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
JPWO2015064453A1 (ja) 2013-11-01 2017-03-09 株式会社糖鎖工学研究所 チオール基を有するｄ−体またはｌ−体アミノ酸誘導体の製造方法
CA2933511A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations
KR20160098426A (ko) 2013-12-17 2016-08-18 라보라토리오스 델 드라. 에스테브.에스.에이. 가바펜티노이드들 및 시그마 리셉터 리간드들 조합
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
IL267306B (en) 2016-12-16 2022-07-01 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
BR112021006004A2 (pt) 2018-10-11 2021-06-29 Sanifit Therapeutics S.A. inositol fosfatos para o tratamento de calcificações ectópicas.
JP7649999B2 (ja) * 2019-10-25 2025-03-24 国立大学法人京都大学 タウオパチーの予防又は治療剤
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Also Published As

Publication number Publication date
SE423385B (sv) 1982-05-03
ES443723A1 (es) 1977-04-16
FR2294697B1 (forum.php) 1978-07-28
DE2460891C2 (de) 1982-09-23
NL181006C (nl) 1987-06-01
DE2460891A1 (de) 1976-07-01
FI62282B (fi) 1982-08-31
LU74058A1 (forum.php) 1976-07-20
CA1052811A (en) 1979-04-17
ATA975075A (de) 1977-05-15
JPS5324064B2 (forum.php) 1978-07-18
AU8774175A (en) 1977-06-23
DK147706B (da) 1984-11-19
NL7514900A (nl) 1976-06-23
FR2294697A1 (fr) 1976-07-16
US4024175A (en) 1977-05-17
AT340892B (de) 1978-01-10
GB1465229A (en) 1977-02-23
IE42382B1 (en) 1980-07-30
CH612664A5 (forum.php) 1979-08-15
DK581475A (da) 1976-01-22
FI62282C (fi) 1982-12-10
CH612666A5 (forum.php) 1979-08-15
JPS5188940A (forum.php) 1976-08-04
BE836835A (fr) 1976-06-18
IE42382L (en) 1976-06-21
CH612665A5 (forum.php) 1979-08-15
DK147706C (da) 1985-05-13
NL181006B (nl) 1987-01-02
SE7514442L (sv) 1976-06-22

Similar Documents

Publication Publication Date Title
FR2294697B1 (forum.php)
FR2256951A1 (forum.php)
FI751462A7 (forum.php)
FR2260040A1 (forum.php)
FI753145A7 (forum.php)
AU7459474A (forum.php)
AU495930B2 (forum.php)
AU485022B2 (forum.php)
FI150674A7 (forum.php)
DE2444727A1 (forum.php)
AU7465674A (forum.php)
AU481220A (forum.php)
BG19816A1 (forum.php)
BE827400A (forum.php)
AU482307A (forum.php)
AU482110A (forum.php)
AU481934A (forum.php)
AU481898A (forum.php)
AU481798A (forum.php)
AU481597A (forum.php)
AU479523A (forum.php)
AU480925A (forum.php)
AU480902A (forum.php)
BE833391A (forum.php)
BE836685A (forum.php)

Legal Events

Date Code Title Description
MA Patent expired
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L56

Extension date: 20001219

MA Patent expired

Owner name: WARNER-LAMBERT COMPANY